OA12709A - Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxa-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-YL)-5-(2-pyridyl)quinzoline. - Google Patents

Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxa-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-YL)-5-(2-pyridyl)quinzoline. Download PDF

Info

Publication number
OA12709A
OA12709A OA1200400094A OA1200400094A OA12709A OA 12709 A OA12709 A OA 12709A OA 1200400094 A OA1200400094 A OA 1200400094A OA 1200400094 A OA1200400094 A OA 1200400094A OA 12709 A OA12709 A OA 12709A
Authority
OA
OAPI
Prior art keywords
formulation
amino
pyridyl
dimethoxy
methanesulfonamido
Prior art date
Application number
OA1200400094A
Other languages
English (en)
Inventor
John Douglas Davis
Michael John Humphrey
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA12709A publication Critical patent/OA12709A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA1200400094A 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxa-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-YL)-5-(2-pyridyl)quinzoline. OA12709A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
OA12709A true OA12709A (en) 2006-06-26

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400094A OA12709A (en) 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxa-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-YL)-5-(2-pyridyl)quinzoline.

Country Status (32)

Country Link
EP (1) EP1434570B8 (no)
JP (1) JP4131471B2 (no)
KR (1) KR20050032510A (no)
CN (1) CN1568180A (no)
AP (1) AP2004003001A0 (no)
AR (1) AR036782A1 (no)
AT (1) ATE303135T1 (no)
BR (1) BR0213196A (no)
CA (1) CA2461168A1 (no)
CO (1) CO5560534A2 (no)
DE (1) DE60205925T2 (no)
DK (1) DK1434570T3 (no)
DO (1) DOP2002000464A (no)
EA (1) EA006168B1 (no)
ES (1) ES2246017T3 (no)
GB (1) GB0124455D0 (no)
GT (1) GT200200184A (no)
HR (1) HRP20040261A2 (no)
HU (1) HUP0600064A3 (no)
IL (1) IL160969A0 (no)
IS (1) IS7179A (no)
MA (1) MA27075A1 (no)
MX (1) MXPA04003293A (no)
NO (1) NO20041520L (no)
OA (1) OA12709A (no)
PA (1) PA8556001A1 (no)
PE (1) PE20030551A1 (no)
PL (1) PL369666A1 (no)
SV (1) SV2004001279A (no)
UY (1) UY27477A1 (no)
WO (1) WO2003032956A1 (no)
ZA (1) ZA200401976B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
HUE046285T2 (hu) 2013-03-14 2020-02-28 Amgen Inc Omecamtiv mecarbil sói és eljárás a só elõállítására
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69008526T2 (de) * 1990-07-02 1994-08-18 Bend Res Inc Asymmetrische mikroporöse Kügelchen für regulierbare Freigabe.
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
UA72311C2 (uk) * 2000-03-03 2005-02-15 Пфайзер Інк. Мезилат 4-аміно-6,7-диметокси-2-(5-метансульфонамідо-1,2,3,4-тетрагідроізохінол-2-іл)-5-(2-піридил)хіназоліну та поліморфні форми

Also Published As

Publication number Publication date
PE20030551A1 (es) 2003-06-26
DE60205925D1 (de) 2005-10-06
EP1434570A1 (en) 2004-07-07
HUP0600064A2 (en) 2006-06-28
HRP20040261A2 (en) 2004-08-31
KR20050032510A (ko) 2005-04-07
SV2004001279A (es) 2004-02-19
CA2461168A1 (en) 2003-04-24
GT200200184A (es) 2003-05-23
EP1434570B8 (en) 2005-10-26
MA27075A1 (fr) 2004-12-20
NO20041520L (no) 2004-04-05
EA200400431A1 (ru) 2004-08-26
EP1434570B1 (en) 2005-08-31
DE60205925T2 (de) 2006-06-08
AR036782A1 (es) 2004-10-06
BR0213196A (pt) 2004-08-31
CO5560534A2 (es) 2005-09-30
DK1434570T3 (da) 2005-11-07
WO2003032956A1 (en) 2003-04-24
GB0124455D0 (en) 2001-12-05
JP2005507909A (ja) 2005-03-24
ATE303135T1 (de) 2005-09-15
IL160969A0 (en) 2004-08-31
CN1568180A (zh) 2005-01-19
HUP0600064A3 (en) 2007-02-28
UY27477A1 (es) 2003-05-30
IS7179A (is) 2004-03-11
DOP2002000464A (es) 2003-04-15
PL369666A1 (en) 2005-05-02
AP2004003001A0 (en) 2004-03-31
JP4131471B2 (ja) 2008-08-13
PA8556001A1 (es) 2003-07-28
ES2246017T3 (es) 2006-02-01
EA006168B1 (ru) 2005-10-27
ZA200401976B (en) 2004-07-12
MXPA04003293A (es) 2004-07-23

Similar Documents

Publication Publication Date Title
CA2464578C (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
WO2011111818A1 (ja) モサプリドまたはその塩を含む徐放型医薬組成物
JP4789806B2 (ja) パントプラゾール多粒子処方
US7163696B2 (en) Pharmaceutical formulations
JP2002533396A (ja) 徐放性ガランタミン組成物
WO2001035958A1 (en) Carvedilol methanesulfonate
JP2003503341A (ja) 少なくとも一つの適時パルスを生ずる制御された放出用の医薬投与形態
KR20040037026A (ko) 심장병 및 순환성 질병을 치료하고 예방하기 위한 하루1회 요법용 제어방출형 경구 약제학적 조성물
JP2014501224A (ja) 口腔内崩壊錠
TW201442741A (zh) 經遮蔽西羅多辛（Ｓｉｌｏｄｏｓｉｎ）苦味之經口投與製劑
JP2013534242A (ja) ナルブフィンを含有する製剤及びそれらの使用
NO341321B1 (no) Preparat for oral administrering av tamsulosin-hydroklorid og granul med kontrollert frigivelsesformulering omfattende det samme
EP2317980A2 (en) Pharmaceutical compositions of rivaroxaban with modified release properties
KR20080037680A (ko) 1-(4-클로로아닐리노)-4-(4-피리딜메틸)프탈라진 및 ｐｈ조절제를 포함하는 고체 제약학적 조성물
WO2016129140A1 (ja) 口腔内崩壊錠及びその製造方法
CN101754754B (zh) 含有包覆的含药物的颗粒的可分散药片及其制备方法
CA2616012A1 (en) Drug-containing coated fine particle for intrabuccally disintegrating preparation and method of producing the same
OA12709A (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxa-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-YL)-5-(2-pyridyl)quinzoline.
WO2019230937A1 (ja) 溶出性に優れた経口固形製剤
JP2018508501A (ja) タムスロシン塩酸塩含有徐放性顆粒を含む経口用薬剤学的製剤
TWI823471B (zh) 沙庫巴曲纈沙坦鈉緩釋組合物、其製備方法及應用
AU2002341260A1 (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline
WO2011096953A1 (en) Oral antidepressant formulation with reduced excipient load
WO2008062426A2 (en) Formulation of benzazepine derivatives
CA2739611C (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient